THE MINISTRY OF INDUSTRY (SHRI J. VENGAL RAO): (a), (c) and (d) To the extent information is available, INH liquid plain is being marketed by M/s. Warner Hindustan and INH Liquid with Vitamin B6 by M|s. IPCA Labs (P) The details of prices fixed and charged by M|s. IPCA Labs (P) Ltd., are not readily available. The same in respect of M|s. Warner Hindustan are given below

S.No.	Name of product	Composition	Pack size	Price fixed under DPCO 1979	Price fixed under DPCO 1987
1	Isokin Liquid	Isoniazid 100mg/5ml	100 ml	5.07	5.54

(b) The product referred to in the question are Anti-TB drugs and therefore fall under Category I of DPCO, 1987.

Prices of Rifampicin

641. SHRI RAJNI RANJAN SAHU:
DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a number of Anti-TB drugs have not been covered under Category I of the DPCO, 1987;

(b) what are the names of Anti-TB drugs which are being marketed in the country and how many of them have not been covered under price control along with the reasons in each case;

(c) whether it is a fact that his Ministry has not fixed the prices of all major combinations of Anti-TB drugs even after a lapse of one year;

(d) what were the prices fixed for Rifampicin in combination with INH in different packs under DPCO, 1979 and DPCO, 1987;

(e) what is the price at which this combination is being marketed;

(f) when was the price of Rifampicin 450 mg plain as well as in combination was last fixed along with the price fixed;

(g) what was the bulk drug price on which the prices of Rifampicin plain as wellas in combination with INH were fixed; and

(h) whether it is a fact this drug plain as well as in combination falls under category I of DPCO and what is the mark up allowed in each case?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) All Anti-TB drugs identified by the Ministry of Health and Family Welfare for the National T.B. Eradication Programme have been covered under Category I of DPCO, 1987.

(c) No, Sir. ceiling prices have been notified by the Government for all major combinations of INH with hiacetazone and PAS.

(d) and (e) No leader price was fixed for formulations based on Rifampicin in combination with INH under DPCO, 1979. As a number of companies are marketing these formulations details of the current selling prices are not readily available. Ceiling prices for these formulations are being notified.

(f) and (g) The required details to the extent available are given in the enclosed statement. (*See* below). The price fixed by the Government are based on the notified prices of the bulk drugs concerned.

(h) The formulations in question fall under Category I of DPCO, 1987 and MAPE @ 75 per cent of ex-factory cost is permissible for all such cases under DPCO, 1987.

Statement

Sl. No.	Name of the Formulation	Composition	Pack size	Price fixed under DPCO, 1987
1.	Mycorim 450mg. Capsules . . .	Rifampicin 450mg/Cap.	4's Strip	11.32
2.	Isomycorim Capsules	Rifampicin 450mg!+Isoniazid 300mg. per capsules	4's Strip	12.01

Representations to Kelkar committee in regard to wornig identification of certain drugs

642. SHRI HARI SINGH:
DR. (SHRIMATI) SAROJINI MAHISHI:
DR. (SHRIMATI) NAJMA HEPTULLA:

Will the Minister of INDUSTRY be pleased to refer to answer to Starred Question 120 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) whether it is a fact that Kelkar Committee is still functioning;

(b) when was the last extension granted to the Committee and upto what itme the Committee will function;

(c) whether it is a fact that Kelkar Committee received representations in regard to wrong identification of Nandrolone, Phenyl Propionate, Nandrolone Decancate, Ethyl Esterehl, Avapyrazone, Calcium and its salts; Vitamin B1, B2, Vitamin C, Vitamin D-3 and Nicotinamide;

(d) what are the names of the various consumer and medical associations and also the names of Members of Parliament who submitted representation to Kelkar Committee on these drugs upto the 15th July, 1988;

(e) whether it is a fact that Expert Committee has agreed to recommend for price control of these drugs;

(f) whether his Ministry has received the recommendations from the Expert Committee; and

(g) if so, by when action will be taken thereon?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The term of the Kelkar Committee has been exended upto 30th September, 1988.

(c) to (g) Details of representations received from the industry, Organisation/Associations and Members of Parliament regarding inclusion in/exclusion from the price controlled categories of drugs are given in the Statements I, II and III respectively (vide unstarred question 625 supra for Statements I, II and III). The representations have been forwarded to the Kelkar Committee. The reort of the Committee has not been received.

Increase in prices of medicines

643. SHRI HARI SINGH:
DR. (SHRIMATI) SAROJINI MAHISHI:
DR. (SHRIMATI) NAJMA HEPTULLA:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1452 given in the Rajya Sabha on the 9th May, 1988 and state :

(a) what are the basis of price increase of 144 per cent on Actifed Tabs, 102 per cent on Neosporin Eye drops, 108 per cent on Neosporin Powder and 51 per cent on Neosporin Ointment;